Probiotic lactic acid bacteria – the fledgling cuckoos of the gut?

References

• Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev. 2004; 28: 405–40. [PubMed Abstract].
   Google Scholar
• Di Cerbo A, Palmieri B, Aponte M, Morales-Medina JC, Iannitti T. Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol. 2016; 69: 187–203. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Berstad A, Hauso O, Valeur J. Intestinal staphylococcal small colony variants: a cause of medically unexplained physical symptoms?. Microb Ecol Health Dis. 2014; 25: 25817. doi: http://dx.doi.org/10.3402/mehd.v25.25817.
   Google Scholar
• Voltan S, Martines D, Elli M, Brun P, Longo S, Porzionato A, etal. Lactobacillus crispatus M247-derived H2O2 acts as a signal transducing molecule activating peroxisome proliferator activated receptor-gamma in the intestinal mucosa. Gastroenterology. 2008; 135: 1216–27. [PubMed Abstract].
   Google Scholar
• Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014; 121: 91–119. [PubMed Abstract].
   Google Scholar
• Bennet SM, Ohman L, Simren M. Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver. 2015; 9: 318–31. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica. 1982; 5: 185–94. [PubMed Abstract].
   Google Scholar
• Campbell AK, Matthews SB, Vassel N, Cox CD, Naseem R, Chiachi J, etal. Bacterial metabolic ‘toxins’: a new mechanism for lactose and food intolerance, and irritable bowel syndrome. Toxicology. 2010; 278: 268–76. [PubMed Abstract].
   Google Scholar
• Raa J, Berstad A, Valeur J. Forstyrrelser i tarmkanalens redoks-biologi – en oversett sykdomsmekanisme?. NGF-nytt. 2015; 22: 32–6.
   Google Scholar
• Saez-Lara MJ, Gomez-Llorente C, Plaza-Diaz J, Gil A. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int. 2015; 2015: 505878. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Dubourg G, Elsawi Z, Raoult D. Assessment of the in vitro antimicrobial activity of Lactobacillus species for identifying new potential antibiotics. Int J Antimicrob Agents. 2015; 46: 590–3. [PubMed Abstract].
   Google Scholar
• Georgieva R, Yocheva L, Tserovska L, Zhelezova L, Stefanova N, Atanasova A, etal. Antimicrobial activity and antibiotic susceptibility of and spp. intended for use as starter and probiotic cultures. Biotechnol Biotechnol Equip. 2015; 29: 84–91. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Yue T, Pei J, Yuan Y. Purification and characterization of anti-Alicyclobacillus bacteriocin produced by Lactobacillus rhamnosus. J Food Prot. 2013; 76: 1575–81. [PubMed Abstract].
   Google Scholar
• Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, etal. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004; 101: 15718–23. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Berstad A, Valeur J. MikrObesitas” og dens mulige behandling med havregrynsgrøt og kanel. NGF-nytt. 2012; 2012: 10–2.
   Google Scholar
• Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis. 2015; 2: ofv004. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Raoult D. Probiotics and obesity: a link?. Nat Rev Microbiol. 2009; 7: 616. [PubMed Abstract].
   Google Scholar
• Million M, Angelakis E, Paul M, Armougom F, Leibovici L, Raoult D. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog. 2012; 53: 100–8. [PubMed Abstract].
   Google Scholar
• Drissi F, Merhej V, Angelakis E, El Kaoutari A, Carriere F, Henrissat B, etal. Comparative genomics analysis of Lactobacillus species associated with weight gain or weight protection. Nutr Diabetes. 2014; 4: e109. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Kobyliak N, Conte C, Cammarota G, Haley AP, Styriak I, Gaspar L, etal. Probiotics in prevention and treatment of obesity: a critical view. Nutr Metab (Lond). 2016; 13: 14. [PubMed Abstract].
   Google Scholar
• Thuny F, Richet H, Casalta JP, Angelakis E, Habib G, Raoult D. Vancomycin treatment of infective endocarditis is linked with recently acquired obesity. PLoS One. 2010; 5: e9074. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• STOKSTAD EL. Antibiotics in animal nutrition. Physiol Rev. 1954; 34: 25–51. [PubMed Abstract].
   Google Scholar
• Angelakis E, Merhej V, Raoult D. Related actions of probiotics and antibiotics on gut microbiota and weight modification. Lancet Infect Dis. 2013; 13: 889–99. [PubMed Abstract].
   Google Scholar
• Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, Li K, etal. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012; 488: 621–6. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Blaser M. Antibiotic overuse: stop the killing of beneficial bacteria. Nature. 2011; 476: 393–4. [PubMed Abstract].
   Google Scholar
• Honeycutt TC, El KM, Wardrop RMIII, McNeal-Trice K, Honeycutt AL, Christy CG, etal. Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial. Pediatr Crit Care Med. 2007; 8: 452–8. [PubMed Abstract].
   Google Scholar
• Lyra A, Krogius-Kurikka L, Nikkilä J, Malinen E, Kajander K, Kurikka K, etal. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterol. 2010; 10: 110. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Mazurak N, Broelz E, Storr M, Enck P. Probiotic therapy of the irritable bowel syndrome: why is the evidence still poor and what can be done about it?. J Neurogastroenterol Motil. 2015; 21: 471–85. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Ligaarden SC, Axelsson L, Naterstad K, Lydersen S, Farup PG. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol. 2010; 10: 16. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Farup PG, Jacobsen M, Ligaarden SC, Rudi K. Probiotics, symptoms, and gut microbiota: what are the relations? A randomized controlled trial in subjects with irritable bowel syndrome. Gastroenterol Res Pract. 2012; 2012: 214102. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Liu Z, Liu W, Ran C, Hu J, Zhou Z. Abrupt suspension of probiotics administration may increase host pathogen susceptibility by inducing gut dysbiosis. Sci Rep. 2016; 6: 23214. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Berstad A, Raa J, Valeur J. Indole – the scent of a healthy ‘inner soil’. Microb Ecol Health Dis. 2015; 26: 27997,. doi: http://dx.doi.org/10.3402/mehd.v26.27997.
   Google Scholar
• Natarajan R, Pechenyak B, Vyas U, etal. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. Biomed Res Int. 2014; 2014: 568571. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Tohyama K, Kobayashi Y, Kan T, Yazawa K, Terashima T, Mutai M. Effect of lactobacilli on urinary indican excretion in gnotobiotic rats and in man. Microbiol Immunol. 1981; 25: 101–12. [PubMed Abstract].
   Google Scholar
• Weber D, Oefner PJ, Hiergeist A, Koestler J, Gessner A, Weber M, etal. Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome. Blood. 2015; 126: 1723–8. [PubMed Abstract].
   Google Scholar
• Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, etal. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 371: 651–9. [PubMed Abstract].
   Google Scholar
• Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, etal. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001; 121: 580–91. [PubMed Abstract].
   Google Scholar
• Rautava S, Kalliomaki M, Isolauri E. New therapeutic strategy for combating the increasing burden of allergic disease: probiotics-A Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. J Allergy Clin Immunol. 2005; 116: 31–7. [PubMed Abstract].
   Google Scholar
• Vitaliti G, Pavone P, Guglielmo F, Spataro G, Falsaperla R. The immunomodulatory effect of probiotics beyond atopy: an update. J Asthma. 2014; 51: 320–32. [PubMed Abstract].
   Google Scholar
• Barrett E, Ross RP, O'Toole PW, Fitzgerald GF, Stanton C. Gamma-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol. 2012; 113: 411–7. [PubMed Abstract].
   Google Scholar
• Edden RA, Crocetti D, Zhu H, Gilbert DL, Mostofsky SH. Reduced GABA concentration in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2012; 69: 750–3. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Sikorska H, Smoragiewicz W. Role of probiotics in the prevention and treatment of meticillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents. 2013; 42: 47581.
   Web of Science ®Google Scholar